Using Gen AI and ML to Improve Clinical Trials for Pharma Companies

Using Gen AI and ML to Improve Clinical Trials for Pharma Companies

By: Dylan Sikes – News

Monday, February 12, 2024

With a focus on developing Generative AI and Machine Learning solutions targeted at the pharmaceutical industry, this company is launching a new offering to improve clinical trials. NetraMark Holdings Inc. (CSE: AIAI) (OTCQB: AINMF), a generative AI software leader in clinical trial solutions, announced in a press release today the launch of its NetraAI Lab. The offering is designed to make it easier and more affordable for biopharmaceutical companies to experience the benefits of how its NetraAI solution can improve clinical trial success rates. 

Through this offering, NetraMark will apply NetraAI to customers' clinical trial data and seek to identify key variables that drive specific trial outcomes, provide testable hypotheses about the role that these variables play in patient responses and recommend inclusion and exclusion criteria based on these insights that can potentially be used to improve the success of future clinical trials.  

Copyright © 2024 All rights reserved. Republication or redistribution of's content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Canada’s Economy Pivots to Growth in the Fourth Quarter
Shares of this Biotech Holdings Company Up on LOI
Real Estate Tech Stock Finds Mid-Week Success
Most Popular
FREE Newsletter

Back to Top